Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous…
The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in two types of…
Read More...
Read More...
